Australian Public Assessment Report for Lenvatinib mesilate

Lenvatinib was also given orphan status for use in various conditions, including follicular thyroid cancer and metastatic or locally advanced papillary thyroid cancer on 27 December 2012. Approval, on 13 February 2015, was standard (that is, not accelerated), and the drug was not considered by … ................
................